Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The allergen extract contains pollen proteins from several grass species. When placed under the tongue, it is absorbed through the oral mucosa, repeatedly exposing the immune system to the allergens. This promotes regulatory T‑cell activity and IgG4 antibody production, which together suppress IgE‑mediated allergic responses and build tolerance over time.

The dosing regimen for Oralair is individualized by the prescribing physician based on the patient’s age, allergy severity, and clinical response. The prescriber determines the initial dose, titration schedule, and maintenance dose, and patients should follow the specific instructions provided on the prescription label.

Safety data for Oralair in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting therapy.

To request Oralair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Oralair is a sublingual tablet, offering the convenience of at‑home administration compared with subcutaneous immunotherapy (SCIT) that requires clinic visits for injections. Compared with other SLIT tablets such as Grastek, Oralair contains a broader mix of grass‑pollen extracts, which may provide coverage for a wider range of grass species. Choice depends on physician assessment, patient preference, and regional availability.

Oralair tablets should be stored at ambient temperature below 25 °C, in their original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the tablets. Keep them out of reach of children and discard any tablet that appears damaged or discolored.

The tablet is placed under the tongue and allowed to dissolve completely without swallowing or chewing. Patients should remain in an upright position and avoid eating or drinking for at least 30 minutes after administration to ensure optimal absorption through the oral mucosa.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe oral or facial edema, and respiratory distress. Patients should be educated to recognize early signs of a systemic reaction and seek immediate medical attention if symptoms such as throat swelling, difficulty breathing, or widespread hives occur.

Oralair is contraindicated in individuals with a known hypersensitivity to the product or any of its excipients, those with severe uncontrolled asthma, and patients experiencing an acute severe allergic episode at the time of dosing. Caution is also advised for pregnant or breastfeeding women until safety is clarified by a healthcare professional.